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Abstract
Proton therapy is increasing in utilization worldwide at a rapid rate. With 
process improvements in costs, footprints, and continued advances in the delivery 
of care, including intensity modulation and image guidance, proton therapy may 
evolve into standard treatment with photon radiation therapy. This chapter reviews 
process improvements in proton therapy and the application in modern care.
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1. Introduction
In this chapter, issues associated with the current practice and future of proton 
therapy are presented including the costs of operation and financial risks involved 
with developing a program. With process improvements in costs, footprints, and 
continued advances in the delivery of care, including intensity modulation and 
image guidance, proton therapy may evolve into standard treatment with photon 
radiation therapy. In this chapter, process improvements in proton therapy and the 
application in modern care are reviewed.
2. The influence of process improvements in proton delivery systems
Historically, proton therapy has always been perceived as an advantage for radia-
tion oncology. With the first generation of proton therapy units, the advantage of 
sparing normal tissue with precision manipulation of the Bragg peak limiting exit 
dose to normal tissue structures has been viewed as an opportunity to escalate dose 
to tumor targets less amenable to photon therapy and limit dose to normal tissues 
in all body areas. Successful application of proton therapy for patient care has been 
acknowledged as self-evident in areas where sparing of normal tissue was of consid-
erable importance. These situations include critical body locations where exit dose 
would be a distinct disadvantage. Lesions at the skull base treated with curative 
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intent and pediatric malignancies where limiting exit and integral dose would be a 
distinct advantage for amelioration of long-term effects on normal tissue, are some 
examples.
Up until the past decade, there were a limited number of proton facilities world 
wide and access to proton therapy was challenging and elusive. Footprints were 
extremely large and maintenance costs were significant. The planning for proton 
care required unique personnel. Devices to alter the Bragg peak had to be con-
structed for each proton field based on a rigorous process further complicated by 
the lack of volumetric three- and four-dimensional image anatomy to mill devices 
for the appropriate treatment. The team of physicists, dosimetrists, and therapists 
were often not aligned with other department efforts as the processes involved 
with proton therapy care required unique radiation therapy planning tools and 
different manners of therapy execution disparate from those applied to photon 
care. Proton therapy delivery, accordingly, could not function at an enterprise level 
and remained an eclectic subset of patient care units limited by access and avail-
ability. Accordingly, only a few institutions worldwide were able to provide proton 
care treatment delivery. Early generation units were difficult to maintain as they 
required unique engineering skills for daily therapy. Vehicles were not available to 
image validate daily therapy and, often due to the complexity of geometries, only 
a limited number of therapy fields could be treated in a single day further limit-
ing the ability of proton therapy to function at a level commensurate with photon 
management.
Photon therapy delivery processes moved forward more quickly due to the 
nimble application of x-ray therapy tools and the ability to add diagnostic quality 
image guidance and extended collimation to linear accelerators for intensity modu-
lation with and without modulated arc therapy. The footprint for linear accelerators 
was small by relative comparison and many corporate strategies aligned to integrate 
advanced technology imaging and therapeutic process improvements into them. As 
accelerators become more computer controlled, their down time became less associ-
ated with mechanical failure and more associated with computer driven issues. 
Cerrobend blocks were replaced by multi-leaf collimators which provided enhanced 
shaping of the beam both at the beam edge and in a dynamic manner within the 
field itself. Dynamic motion of the multi-leafs permitted alteration in beam inten-
sity creating “beamlets” of radiation which could be aligned to the inverse topog-
raphy of the target and normal tissue. Fluence profiles for photon therapy could be 
modulated and daily treatment reproducibility could be optimized and validated 
with portal dosimeters and adaptive therapy design.
Volume modulated arc therapy for photons has compressed treatment time with 
dynamic and simultaneous harmonization of gantry motion coupled with multi-
leaf motion. This influenced and simplified motion management for radiosurgery 
and daily traditional therapy applications by significantly decreasing the time 
required for daily therapy. As a positive consequence, the risk of patient movement 
and motion of the target away from the intended target of therapy was limited, pro-
viding more security that the targets were correctly treated enhancing the quality of 
daily care. In many series, the quality of care has direct impact on patient outcome, 
therefore improved quality has the potential of maximizing tumor control and 
titration of the therapy effect on normal tissue function [1, 2]. Successful improve-
ments in the application of photon care have moved the field forward at a rapid pace 
and vendors are evaluating the applicability of these improvements to proton care.
In contrast, proton care remained challenged by the footprint and strategy 
behind therapy application. The mechanics of particle delivery improved with 
the development of pencil beam application systems as these systems were 
more facile to apply care than passive scatter systems. Nevertheless, despite the 
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limitations in application strategy, the ability of limiting exit dose and improving 
the geometry of the application of radiation therapy for patient care remained 
alive in the minds of many radiation oncologists, physics application specialists, 
and cyclotron engineers; and, by the early part of the 21st Century, the ideas 
supporting proton delivery became increasingly realistic and able to function at 
an enterprise level [3–7].
Initially, proton systems placed emphasis on traditional models of care which 
had multiple therapy gantries including research gantries aligned with a single cen-
tral source to generate particles. The facilities cost hundreds of millions of dollars to 
construct and maintain, therefore considerable commitment and investment were 
required by all involved to insure a successful outcome for institutions and patients. 
The enthusiasm was generated by clinical altruism and institutional visibility. 
Institutions and facilities used multiple business models to achieve the objectives 
for design, construction, and implementation of care. Often the models were 
built on partnerships between otherwise competing institutions to manage costs. 
Institutions would also partner with business venture firms to share cost and profit. 
Multiple cottage industries grew from these partnerships. Disease areas of high 
patient volume were targeted for application to support the fiscal infrastructure 
of the program. Informatics tools permitted off-site management and planning, 
facilitating the integration of business models [8–15].
The most important change occurred with miniaturization of proton design 
coupled with the integration of tools that have made photon care nimble and 
precise. The production of single gantry systems that could be directly integrated 
into department function has become a working model for the future of particle 
care (Figure 1). These systems offered a much smaller footprint at a significant 
cost reduction, thus making proton care achievable for institutions who otherwise 
could not consider particle therapy. This has evolved into a powerful tool and has 
permitted particle therapy to mature in many parts of the world. Proton care is no 
longer an eclectic sub-specialty of radiation therapy but a dynamic growing compo-
nent of radiation therapy maturing at a rapid rate in parallel to photon care. There 
have been many challenges in reaching this point and more challenges lie ahead. 
Figure 1. 
Single gantry radiation therapy system. Copyright. Creative commons attribution license (CC BY) [16].
Proton Therapy - Current Status and Future Directions
4
Nevertheless, proton care now has a solid footprint in clinical radiation therapy and 
will continue to grow moving forward [17–24].
3. Financial considerations
Proton therapy systems require a strong financial commitment from institutions 
and financial partners. Investments of $200 million and higher were required to 
build centers with multiple gantries. Investors and institutions needed security to 
insure their investment would merit the expense required for construction, opera-
tion, and maintenance. Business models were designed anticipating predictable 
high-volume radiation therapy. Many of these models were based on the treatment 
of prostate cancer anticipating a paradigm shift away from surgery and photon-
based therapy strategies. This was an attractive model as dose distribution to normal 
tissues including bladder and rectum appeared superior and would accordingly be 
supported by insurers and third-party support systems.
Many payors, however, chose not to support proton therapy for prostate care due 
in part to the successful application of advancements in using photons. The ability 
to alter fluence profiles over the entire radiation therapy treatment field coupled 
with the ability to document positioning with kilovoltage (kV) fiducial tracking and 
volumetric computer tomography created a significant paradigm shift in the treat-
ment of prostate cancer. Multiple photon-based trials demonstrated both outstand-
ing local control and minimal treatment sequelae with photon based image-guided 
intensity-modulated radiation therapy (IMRT) and, as such, it was challenging to 
demonstrate clinical improvement with the use of protons despite unambiguous 
improvements in dose distribution to normal tissue with proton care. Because a 
statistically significant improvement in normal tissue outcome could not be dem-
onstrated between photon and proton therapy, many payors decided not to support 
the cost of proton therapy for prostate cancer. A typical comparable American 
Medical Accounting and Consulting (AMAC) reimbursement for a cancer patient 
treated with proton therapy versus intensity modulated photon therapy results in 
a greater than $16 thousand increase per patient revenue for proton therapy, hence 
the reason for pause in approval and requirement of clinical improvement outcome 
data to re-visit the discussion.
For most radiation therapy departments, the three largest disease treatment 
groups are breast cancer, thoracic/lung cancer, and genitourinary (GU)/prostate 
cancer. In many departments with standard surgical sub-specialty care institutional 
colleagues, these disease groups in aggregate, comprise 25–35% of the patient 
population on treatment. Therefore, to justify proton care with multiple gantry 
platforms, a common therapy disease site would help secure the fiscal security 
required for investment. Business models were often driven by predictions for 
prostate cancer management and when reimbursement models changed, and 
prostate cancer therapy was no longer supported by insurance carriers, many 
proton centers faced fiscal uncertainty. There were centers in the United States that 
entered bankruptcy and one center closed because of fiscal challenges maintaining 
the facility. The future of multiple gantry centers became less certain. Institutions 
in large metropolitan areas with an integrated prominent bandwidth for a referral 
network remained successful, however it became less certain that proton care could 
successfully enter geographic regions of more limited population centers in medi-
cal markets with competition. For proton centers to survive the new era of fiscal 
compromise where reimbursement may not be commensurate with investment and 
cost, proton application would need to become more cost effective and demonstrate 
clinical advantage in multiple disease groups.
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Approximately 12 years ago, single gantry proton units came to market and 
the paradigm of care changed. The units had a more attractive cost at a fraction 
of multi-gantry facilities with a smaller footprint for construction and mainte-
nance. Although the initial units had challenges with image guidance and nimble 
platforms for treatment execution, over the past decade process improvements 
in these areas have made the execution of proton treatment the near equivalent 
of photon therapy. Coupled with the advantage of dose distribution, institutions 
have been able to revisit their cancer center specific strategic plans and incor-
porate proton units into their capital equipment plans for the next generation of 
radiation oncology. Companies manufacturing proton single gantry cyclotrons 
may or may not be aligned with the production of photon linear accelerators. 
Those aligned may have a long-term advantage in their ability to integrate photon 
and proton planning into a single overarching system and more easily transfer 
patient care between units on an as needed basis. Nevertheless, it is a unique 
time in the history of radiation therapy as proton care has now moved to enter-
prise function with multiple proton facilities throughout the United States and 
the world. Many institutions are planning for proton construction in the near 
future. The investment must be planned with a strategy for growth. Although 
the cost is significantly less than previous multiple gantry systems, cost remains 
significantly higher than photon therapy and the advantages must balance the 
investment for financial security. Although in selected circumstances proton 
care is reimbursed by insurance carriers at a higher level per treatment, it is not 
clear and in fact unlikely the reimbursement models will remain at current levels. 
Proposals over the past several years have suggested movement to a single model 
of reimbursement agnostic of therapy approach, implying that proton and photon 
case reimbursement including the use of advanced technologies would be identi-
cal. Although these models for reimbursement have not yet been implemented, 
institutions planning on developing proton care must remain cognizant that 
reimbursement models will likely change in the near future and a strategy for 
both growth and cost containment must be incorporated into the business plan for 
proton development moving forward [25, 26].
4. Adjustments in proton footprint for future care
Significant progress has been made in the development of proton delivery 
systems and cost has evolved to become achievable with effort for institutions who 
could otherwise not consider particle therapy. The technology has made consider-
able progress over the past two decades and will continue to improve. The footprint 
will become smaller and more compressed. This will increase the likelihood that 
proton facilities can be located in closer approximation to traditional photon 
facilities and conceivably be placed in photon vaults, saving cost of construction. 
Current single gantry optimal building strategies build out from facilities with a 
general cost of $6 million for construction costs. Being able to build and install 
particle therapy into traditional departments and photon vaults will save cost and 
serve to bring particle therapy to the staff creating synergy for all department full 
time employees (FTE). Photon care today has extraordinary image guidance and 
intensity modulation with tools for optical tracking and patient care has never been 
better. This has created nimble treatment that can be validated and treated in a few 
minutes. The goal for proton care moving forward is to integrate to advantages of 
photon care into the proton footprint. This would include tools for image guidance, 
beam precision, and optical tracking as well as create synergy and integration 
among the physics and therapy staff [25, 26].
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This idea has begun to mature. Image guidance has played an important role in 
providing security in daily patient setup well beyond what could be achieved with 
kV imaging. The addition of both diagnostic kV imaging and cone beam computer 
tomography has brought a new era to radiation treatments and has permitted 
radiation oncologists to titrate target volumes due to the confidence in daily set 
up. Proton centers are beginning to integrate imaging strategies into daily care 
including ring-based geometries to secure volumetric set up for treatment. Many 
centers now use multi-leaf collimators to provide intensity modulation including 
strategies to apply small volume radiosurgery with proton therapy. Flash therapy is 
being applied with electrons, photons, and now protons. The more particle care can 
synergize with the advances in photon care, proton care can be easily integrated into 
the work flow of department management.
Artificial intelligence will play an increasing role in the daily practice of radia-
tion oncology. Even early iterations of artificial intelligence have provided both 
consistent normal tissue contouring and enhancement of planning function for 
dosimetry and physics planning staff. This saves time and effort permitting plan-
ning staff to focus more on the important planning tasks at hand and could serve to 
introduce particle planning strategies to all planning staff. An appropriate economy 
of scale for staff could be created so not to segregate staff into separate divisions 
as contouring of normal tissue and tumor targets is therapy agnostic. The ultimate 
therapy approach can be applied for photon/proton per assessment of benefit to the 
patient including insurance requirements. Department functions can become more 
transparent between staff as artificial intelligence matures and ultimately resides 
in a single planning system that manufacturers that participate in developing both 
photon and proton treatment units. Staff can become familiar with the tools of 
therapy as the processes of plan development and therapy execution become more 
parallel and aligned [27].
5. Strategy for the future
Historical models of radiation oncology departments offering photon and 
proton care had FTE including physicists and therapists that were skilled in their 
specific area with little overlap in function, therefore there were redundancies and 
no economy of scale for the FTE. This was due to the disparate nature of treat-
ment planning and treatment delivery creating silos in the department without 
hybrid function. Even engineering skills and requirements were disparate and FTE 
functioned in independent areas with minimal overlap in work flow, resulting in 
increased cost and challenging to function with backfill staff support between the 
teams. The process of care and the planning of care were and currently remain 
different requiring separate computer operation systems further separating work 
flow. The infrastructure required for proton care was unique and planning for care 
required separate modeling systems. This was necessary by default and hybrid 
strategies to provide an economy of scale for individual FTE could not be devel-
oped because the employee skill set could not co-exist in a hybrid model. Even 
today, many proton manufacturers do not participate in developing photon patient 
care. As reimbursement models change and become agnostic to radiation therapy 
technique, there will be more effort to move this strategy into a different pathway 
as reimbursement for proton care will become more aligned with photon care. It 
will be necessary for departments to provide hybrid strategies as reimbursement 
becomes photon/particle transparent and internal economies of scale for patient 
care will need to be enhanced [25–38].
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To accomplish these important objectives, proton care of the future will need 
to become more cost aligned with current costs of photon care. Cost for photon 
care has increased over the past decade as process improvements in intensity 
modulation, image guidance, and optical tracking have become commonplace in a 
department. Computer operations require cost including upgrades and institutions 
need to be prepared to undergo constant process improvements and support these 
improvements for cost. Cost of vault construction and modern linear accelerators 
can now exceed $5 million for photon care as the cost includes tools for optical 
tracking, intensity modulation, and image guidance.
The current cost of vault construction and build out for single gantry cyclotron 
function is now in the minimal range of $30 million with $6 million dedicated to 
vault construction as a build out from the primary facility and $24 million for the 
equipment. It is likely that adding many of the current areas of flexibility now used 
with routine for photon care including optical tracking, intensity modulation, and 
image guidance will increase cost for the next iterative application of proton care. 
Proton care will need to continue to work on cost and the current belief is cost will 
decrease with volume-based adjustments. Specifically, once proton units become 
more numerous and populated worldwide, cost may decrease over time as expenses 
can be modified based on the redundancy of production. This will require further 
miniaturization of the proton footprint in a manner similar to the photon footprint 
including the computer operations. Couch function for proton care will likewise 
need to adjust to the flexibility of protons including further improvements in the 
precision of proton care delivery. This has begun with the introduction of multi-
leaf collimation. Photon multi-leaf collimation has provided field size adjustment 
with significant precision and efforts to apply this technology will further support 
proton care in ultra-small targets identical to photons. The stereotactic body radio-
surgery tools have been well developed for photons. Given the improved radiation 
therapy dose distribution for protons, applying radiosurgery techniques for protons 
in the similar manner used for photon care will improve patient outcome including 
the capacity for motion management.
Continued miniaturization and re-modeling of existing technology for the 
generation of protons will continue to decrease cost with smaller footprints and 
more limited shielding. This will continue to make proton care more affordable. 
One of the smallest footprints is generated by a high-energy superconducting 
synchrocyclotron which eliminates the need for complex magnet-guided beam-
lines. This also serves to optimize power consumption further reducing cost of 
maintenance. Designs facilitating upgrades of hardware are important to limit 
future costs. Technologies including dielectric wall accelerator units and proton 
plasma acceleration may pivot the strategy for the infrastructure for these units 
and promote further change in cost and footprint. Of equal importance, protons 
are now being used to treat malignancies of all cell types and tissues of origin. 
Independent of cell type and body site of disease, dose distribution is simply bet-
ter with protons and the improvements can be applied across all epithelial and liq-
uid disease sites. The challenge has uniformly been in proof of principle. Although 
dose to normal tissue can be titrated with protons in nearly all body areas, demon-
strating with statistical significance the benefit of dose reduction is not a simple or 
straightforward task as scoring a null event for significance requires large cohorts 
of patients with decades of follow up. This creates a challenge to score tissues of 
limited self-renewal capacity such as heart and lung for late effects. While many 
feel the advantage or proton dosimetry is self-evident, it remains to be proven to 
payers that the improvements provide the efficacy to balance the cost. Both areas 
require process improvements as we are obliged to provide effective and safe care 
Proton Therapy - Current Status and Future Directions
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with proton manufacturers remaining responsible for cost reduction to promote 
its application at an enterprise level [28–38].
6. Summary
Since its inception, proton care has been an important component of radiation 
therapy. Because of the challenges of size and infrastructure, centers of opera-
tion were few and application of proton care remained eclectic as photon therapy 
matured at a rapid rate with significant process improvements for treatment 
delivery and validation. Proton centers became more numerous during the past two 
decades in the United States and with the development of single gantry systems, 
smaller units became commercially available at a more affordable cost that could be 
reached by health care institutions and private oncology systems. The number of 
centers has significantly increased over the past decade and protons are now used 
with more routine in multiple disease sites worldwide. In selected clinical protocols, 
twenty-five percent of pediatric patients treated with radiation therapy are treated 
with protons. Proton dosimetry has provided decrease dose to normal tissue in all 
disease sites with therapeutic advantages in all body areas. At one level, if cost can 
be contained and hybrid workflow strategies can be developed, one can envision 
proton care as an equal partner to photon care for the next generation of radiation 
oncologists [34, 35].
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